Artemether (CAS 71963-77-4) Product Guide
Table of Contents
1. Product Specifications & Comparative Analysis
| Parameter | Artemether | Artemisinin | Artesunate |
|---|---|---|---|
| CAS Number | 71963-77-4 | 63968-64-9 | 88495-63-0 |
| Molecular Formula | C16H26O5 | C15H22O5 | C19H28O8 |
| Solubility | Lipophilic | Low water solubility | Water-soluble |
| Half-life | 4-11 hours | 2-5 hours | 0.5-1 hour |
2. Therapeutic Applications & Mechanisms
Primary Indications:
- First-line treatment for Plasmodium falciparum malaria
- Severe malaria combination therapy
- Antiparasitic applications in veterinary medicine
Mechanism of Action:
Artemether demonstrates schizonticidal activity through heme-mediated decomposition, generating free radicals that disrupt parasite endoplasmic reticulum functions.
3. Clinical Usage Protocols
Recommended Administration:
| Patient Type | Dosage | Duration |
|---|---|---|
| Adults | 4 mg/kg initial dose | 3-day course |
| Pediatric | 3.2 mg/kg loading dose | 5-day regimen |
4. Implementation Case Studies
Case 1: Regional Malaria Elimination Program (West Africa, 2022)
Implementation of artemether-lumefantrine combination therapy reduced treatment failure rates from 18% to 3.2% within 9 months.
Case 2: Hospital Emergency Protocol (Southeast Asia, 2023)
Intravenous artemether administration decreased severe malaria mortality by 41% compared to quinine-based treatments.
5. Verified Client Implementations
Pharmaceutical Manufacturer A:
– Annual procurement: 850kg
– Application: ACT production
– Formulation: 20mg tablets with 120mg lumefantrine
Research Institute B:
– Usage: Antiparasitic drug development
– Study parameters: Comparative efficacy against artesunate
– Outcome: 28% faster parasite clearance rate
6. Professional Consultation
Contact our pharmaceutical experts for:
- Custom synthesis specifications
- GMP certification documentation
- Clinical trial support packages
Email: info@vivalr.com
Phone: (86) 15866781826



评论
目前还没有评论。